These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35356844)

  • 21. Chronic heart failure: the role of di vericiguat.
    Caminiti G; Sposato B; Volterrani M
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C316-C318. PubMed ID: 37125270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
    Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL; Liang B
    Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
    Kassis-George H; Verlinden NJ; Fu S; Kanwar M
    Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of vericiguat in heart failure: a meta-analysis.
    Ma J; Guo S; Jiang H; Li B
    J Int Med Res; 2023 Mar; 51(3):3000605231159333. PubMed ID: 36896460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.
    Defilippi CR; Alemayehu WG; Voors AA; Kaye D; Blaustein RO; Butler J; Ezekowitz JA; Hernandez AF; Lam CSP; Roessig L; Seliger S; Shah P; Westerhout CM; Armstrong PW; O'Connor CM;
    J Card Fail; 2023 Apr; 29(4):448-458. PubMed ID: 36634811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
    Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
    J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
    Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
    JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
    Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M;
    Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vericiguat, organic nitrates, and heart failure in African Americans.
    Ilonze OJ; Guglin M
    Int J Cardiol; 2021 Sep; 338():136-137. PubMed ID: 34157357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.
    Vannuccini F; Campora A; Barilli M; Palazzuoli A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
    Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
    Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vericiguat: First Approval.
    Markham A; Duggan S
    Drugs; 2021 Apr; 81(6):721-726. PubMed ID: 33770393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble Guanylate Cyclase Stimulators in Heart Failure.
    Kansakar S; Guragain A; Verma D; Sharma P; Dhungana B; Bhattarai B; Yadav S; Gautam N
    Cureus; 2021 Sep; 13(9):e17781. PubMed ID: 34659992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.